Antimycotics for systemic use. Triazole derivatives. ATC Code J02А С01.

Indications to Use:

Treatment of such diseases in adults as:

– cryptococcal meningitis;

– coccidioidomycosis;

– invasive candidiasis;

– candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus candidum, chronic candidiasis of the skin and mucous membranes;

– chronic atrophic candidiasis (candidiasis caused by the use of dentures) with inefficiency of local dental hygiene means;

– vaginal candidiasis, acute or recurrent, when local therapy is inappropriate;

– Balanitis Candida, when local therapy is inappropriate;

– dermatomycosis, including mycosis of feet, mycosis of smooth skin, inguinal dermatomycosis; multicolored lichen and candidal skin infections, when systemic therapy is inappropriate;

– dermatophytic onychomycosis, when the use of other medicines is inappropriate.
Prevention of such diseases in adults as:

– relapse of cryptococcal meningitis in patients with a high risk of its development;

– relapse of candidiasis of the oropharynx or esophagus in HIV-infected patients with a high risk of its development;

– decrease in the frequency of recurrences of vaginal candidiasis (4 or more cases per year);

– prophylaxis of candidiasis infections in patients with prolonged neutropenia (for example, patients with malignant blood diseases who receive chemotherapy or patients in the transplantation of hematopoietic stem cells).

Children. The drug can be used in the form of capsules in this category of patients, when children are able to safely swallow the capsule, usually at the age of 5 years.

The drug is used in children for the treatment of candidiasis of the mucous membranes (candidiasis of the oropharynx, candidosis of the esophagus), invasive candidiasis, cryptococcal meningitis and for the prevention of candidal infections in patients with reduced immunity. The drug can be used as maintenance therapy to prevent the recurrence of cryptococcal meningitis in children at high risk of its development.

Therapy can begin before the results of culture and other laboratory studies; after receiving the results, antibiotic therapy should be adjusted accordingly.